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VAP = ventilator-associated pneumonia; VRE = vancomycin-resistant enterococci.
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There is general consensus that in-hospital antimicrobial
resistance influences patient outcome and the allocation of
resources [1]. Antibiotic resistance is occurring more
rapidly and more frequently all over the world, with Gram-
negative bacilli and Gram-positive bacteria being important
causes of hospital-acquired infections [2,3]. In many cases,
there are few effective antimicrobial agents, particularly
with methicillin-resistant and vancomycin-resistant Staphy-
lococcus aureus and Gram-negative bacteria [4,5].
This review will focus on strategies aimed at optimizing
antibiotic use within intensive care units. This is an impor-
tant issue for intensivists because of the acute nature of
critically ill patients and the increased likelihood of antimi-
crobial resistance within intensive care units [6,7]. There
are numerous pressures within intensive care units that
potentiate the emergence of antibiotic-resistant infections:
the frequent use of broad spectrum antibiotics, the crowd-
ing of patients with complex medical problems into small
areas of the hospital, and the presence of more chronically
and acutely ill patients who require prolonged hospitaliza-
tions and often harbour antibiotic-resistant bacteria [8,9].
Furthermore, reductions in nursing and other staff through
economic pressures increase the likelihood of person-to-
person transmission.
Preventing nosocomial infections is important to reduce
the use of antibiotics [1]. Many hospitals have reduced the
number of nosocomial infections through infection control
programmes and novel interventions [10,11]. By optimiz-
ing the use of antibiotics within intensive care units,
patient outcomes are improved, better initial antibiotic
administration is provided, and the chances of further
antibiotic resistance are minimized [12–14]. In addition to
the strategies described in this review (Table 1), clinicians
must insure that antibiotic administration satisfies minimal
requirements, such as proper dosing, drug interval admin-
istration, monitoring drug levels, and avoiding harmful drug
interactions. Not satisfying these minimal requirements will
lead to patients receiving suboptimal antibiotic concentra-
tions, which increases the likelihood of treatment failures,
antibiotic resistance, and patient toxicity [15,16].
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Abstract
Antibiotics are one of the most common therapies administered in the intensive care unit setting. In
addition to treating infections, antibiotic use contributes to the emergence of resistance among
pathogenic microorganisms. Therefore, avoiding unnecessary antibiotic use and optimizing the
administration of antimicrobial agents will help to improve patient outcomes while minimizing further
pressures for resistance. This review will present several strategies aimed at achieving optimal use of
antimicrobial agents. It is important to note that each intensive care unit should have a program in place
which monitors antibiotic utilization and its effectiveness. Only in this way can the impact of
interventions aimed at improving antibiotic use (e.g. antibiotic rotation, de-escalation therapy) be
evaluated at the local level.
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Antimicrobial optimization strategies
Guidelines/protocols
Antibiotic administration guidelines/protocols developed
locally or by national societies potentially avoid unneces-
sary antibiotic administration and increase therapeutic
effectiveness. Unfortunately, even well-developed guide-
lines/protocols may not translate into widely accepted
treatment algorithms. Some deviation from guidelines/pro-
tocols is expected because medical decision-making
should be guided by an individual patient’s characteristics
and the judgement and experience of the caregivers.
Locally developed guidelines therefore often have the best
chance of being accepted by local health care providers
and hence of being implemented [17].
The potential benefits of guidelines/protocols have been
well demonstrated by the Latter Day Saints Hospital in
Salt Lake City, Utah, where a computerized system guides
antibiotic administration. The system automatically identi-
fies and minimizes adverse drug effects due to antibiotics
[18,19] and has reduced inadequate administration com-
pared with physician prescribing patterns [20]. The
system has also been associated with stable antibiotic
susceptibility patterns over time, both for Gram-positive
and Gram-negative bacteria [21]. It has most recently
been shown to significantly reduce orders for drugs to
which patients were allergic, the number of adverse
events caused by antibiotics, and the total number of
antibiotic doses prescribed, as well as the medical costs
associated with antimicrobial agents [22].
Non-automated or partially automated systems, usually
driven by hospital-based quality improvement teams, have
demonstrated similar results [23]. Bailey et al randomized
patients so that pharmacists contacted some of their
physicians with recommendations for discontinuing intra-
venous antibiotics [24]. The pharmacists’ intervention sig-
nificantly reduced antibiotic doses and mean antibiotic
costs, but was associated with increased labour costs.
Similarly, Leibovici et al developed a problem-oriented
decision support system that significantly reduced the
injudicious or inadequate administration of antibiotics, par-
ticularly in patients infected with multiresistant Gram-nega-
tive isolates, enterococci, and S. aureus [25]. As
technology, such as handheld computers and portable
communication devices, becomes widely available there is
more opportunity to influence treatment protocols.
Two groups of investigators recently demonstrated the
use of protocols/guidelines for the management of ventila-
tor-associated pneumonia (VAP). Singh et al used a
scoring system to identify patients with suspected VAP
who could be treated with 3 days of antibiotics as
opposed to the conventional practice of 10–21 days [26].
Patients receiving the shorter course had similar clinical
outcomes to the patients receiving the longer course but
with fewer subsequent superinfections attributed to anti-
biotic-resistant pathogens. Ibrahim et al employed a phar-
macist-directed protocol in intensive care units to reduce
the administration of antibiotics for suspected VAP to
8.1 ± 5.1 days from 14.8 ± 8.1 days (P < 0.001) [27].
Restricting the hospital formulary
Restricting the use of certain antibiotics or classes of
antibiotics has been shown to reduce pharmacy expenses
and adverse drug reactions from the restricted drug or
drugs [28]. This approach is generally applied to drugs
with broad spectrums of action (such as imipenem), where
antibiotic resistance emerges rapidly (as with third-genera-
tion cephalosporins) and where toxicity is readily identified
Table 1
Practices promoting the optimization of antimicrobial use in the intensive care unit setting
Provide adequate initial treatment of serious infections (e.g. pneumonia, bloodstream)
Awareness of predominant causative pathogens
Up to date unit-specific pathogen antibiograms
Drainage of abscesses, empyema cavities, other infected fluid collections
Removal of infected foreign bodies (e.g. central venous catheters)
Monitor serum drug concentrations when appropriate to achieve therapeutic levels
Minimize antibiotic pressures promoting resistance
Avoid prolonged courses of empiric antibiotic therapy
Consider de-escalation of antibiotics based on available microbiologic data and clinical course
Use narrow spectrum antibiotics when supported by clinical situation and culture data
Establish appropriate thresholds for prescribing antibiotics
Develop predetermined criteria for the discontinuation of antimicrobial therapyr
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(such as with aminoglycosides). However, not all experi-
ences have been uniformly successful. One survey of 88
hospitals found that the average total expenditure on
antimicrobial agents between 1993 and 1994 increased
by $300 per occupied bed, despite over 60% of the
hospitals restricting the use of antibiotics [29]. Of the 88
hospitals, only 7% decreased costs by $500 or more per
occupied bed. The most common reasons for these
decreases were restructuring of pricing contracts and
education programmes aimed at reducing the use of
antibiotics. Replacing one antimicrobial with another only
lead to increased use of other antimicrobials, rather than
the replacement, and did not produce any savings. Fur-
thermore, restricting the use of certain antimicrobials can
promote antibiotic resistance to other antimicrobials [30].
To date, mainly due to methodological problems, it has
been difficult to demonstrate that restricting hospital formu-
laries is effective in curbing the emergence of resistance or
improving antimicrobial efficacy. However, the restrictions
have been successful in outbreaks of infection with anti-
biotic-resistant bacteria, particularly in conjunction with infec-
tion control practices and antibiotic educational activities.
Hospitals in Greece during the late 1980s had high levels
of antimicrobial resistance among Gram-negative bacteria,
particularly in Enterobacter, Klebsiella, and Acinetobacter
species, and Pseudomonas aeruginosa [31]. To combat
this, one hospital introduced a structured programme
involving: specific rules for hospital hygiene; educational
programmes for small groups of healthcare providers; and
an antibiotic policy aimed at restricting their overall use,
especially those with broad spectra. Imipenem, the newer
fluoroquinolones, vancomycin, aztreonam, and the third-
generation cephalosporins could only be ordered with a
specific antibiotic request form that, from 1991 onwards,
had to be approved by an infectious diseases specialist. A
3-year audit between 1992 and 1995 demonstrated
decreased use of the restricted antibiotics compared with
that before 1991, without there being an increase in the
use of non-restricted antibiotics. There was also an asso-
ciated reduction in antimicrobial resistance, except resis-
tance to fluoroquinolones, which were subsequently
removed from the hospital’s formulary. All this was
achieved despite increasing levels of antimicrobial resis-
tance across Europe during the same time [2,3].
Outbreaks of diarrhoea associated with Clostridium diffi-
cile are often linked to antibiotic use and misuse. In one
experience, an outbreak that was caused by a clonal
isolate of clindamycin-resistant C. difficile was associated
with increased use of clindamycin despite the presence of
infection control practices [32]. To restrict the use of clin-
damycin, all requests for its use had to be approved by a
consultant in infectious diseases. This resulted in an
overall reduction in its use, a sustained reduction in the
mean number of cases of diarrhoea associated with C. dif-
ficile, and an increase in clindamycin susceptibility among
C. difficile strains. Although this lead to increased use of
antibiotics with anti-anaerobic activity, including cefotetan,
ticarcillin-clavulonate, and imipenem, the hospital saved
money as a result of the decreased incidence of diarrhoea
associated with C. difficile.
Restricting hospital formularies may be useful in the
control of outbreaks due to specific bacterial pathogens or
when other infection control practices have been unsuc-
cessful. They cannot, however, be viewed as an alternative
to judicious use of antibiotics, since resistance is likely to
develop in the antibiotics that are not restricted [30,33].
Scheduled changes in antibiotic
To combat an outbreak of infection from extended spec-
trum B-lactamase-producing Klebsiella, Rahal et al intro-
duced an antibiotic guideline into their hospital that
significantly restricted the use of cephalosporins [30]. The
use of cephalosporins was reduced by 80.1%, which was
accompanied by a 44.0% reduction in infection and colo-
nization with extended spectrum B-lactamase-producing
Klebsiella. At the same time, however, the use of
imipenem increased by 140.6% and was associated with
a 68.7% increase in the incidence of imipenem-resistant
P. aeruginosa.
Kollef et al examined the influence of a scheduled change
in antibiotic on the incidence of nosocomial infections
among patients undergoing cardiac surgery [34]. In the
6 months preceding the surgery, a third-generation
cephalosporin (ceftazidime) was used for the treatment of
Gram-negative bacterial infections. In the 6 months after
the surgery, a fluoroquinolone (ciprofloxacin) was used.
Unexpectedly, the overall incidence of VAP was signifi-
cantly reduced in the 6 months after the surgery com-
pared with the 6 months before, primarily because of a
significant reduction in the incidence of VAP attributed to
antibiotic-resistant Gram-negative bacteria. A lower inci-
dence of antibiotic-resistant Gram-negative bacteraemia
was similarly observed in the 6 months after the surgery.
This experience was followed by a series of scheduled
antibiotic changes for the treatment of suspected Gram-
negative bacterial infections among patients admitted to
the medical and surgical intensive care units [35]. Overall,
the prescription of adequate antimicrobial therapy was
statistically increased for Gram-negative bacterial infec-
tions. However, the long-term effectiveness of a limited
number of scheduled antibiotic changes is unknown
owing to the potential for increased emergence of resis-
tance to the newly selected antibiotic classes [30].
Combining antibiotic therapy
The use of combination antimicrobial therapy has been pro-
posed as a strategy to reduce the emergence of bacterial
Available online http://ccforum.com/content/5/4/189resistance, as has been employed for Mycobacterium
tuberculosis [36]. Unfortunately, no convincing data exist
to validate this hypothesis for nosocomial pneumonia [37].
Conclusive data that combination antibiotic therapy for
nosocomial bloodstream infections prevents the subse-
quent emergence of antibiotic resistance is similarly lacking
[38]. Nevertheless, there is some indirect evidence that the
use of combination antimicrobial therapy may be useful.
In the County of Northern Jutland, Denmark, all bacter-
aemia were analysed with regard to antibiotic resistance
over a 14-year period (1981–1995) [39]. A total of 8840
isolates from 7938 episodes of bacteraemia were identi-
fied. The level of resistance to third-generation
cephalosporins, carbapenems, aminoglycosides, and fluo-
roquinolones among Enterobacteriaceae was low (<1%).
The recommended regimen for empirical antibiotic treat-
ment in this region is a combination of penicillin G or ampi-
cillin and an aminoglycoside, which provided an overall
coverage of 94%. This experience suggests that combina-
tion therapy with narrow spectrum agents over prolonged
time periods may help curb resistance to broad spectrum
antibiotics, yet still provide effective treatment of serious
infections to include bacteraemia.
In addition to potentially preventing antibiotic resistance,
combination antimicrobial therapy may be more effective
for providing adequate initial treatment of resistant
pathogens and producing beneficial clinical and microbio-
logic responses. Trouillet et al demonstrated that certain
antibiotic combinations were more likely to provide higher
rates of bacteriologic cure than other combinations for
nosocomial pneumonia within a specific hospital setting
[6]. Brun-Buisson et al similarly showed that, despite the
addition of an aminoglycoside, treatment with ceftazidime
was associated with a greater number of bacteriologic fail-
ures as compared with piperacillin-tazobactam employed
in combination with an aminoglycoside [40].
Antibiotic rotation
The concept of antibiotic class cycling has been advo-
cated as a potential strategy for reducing the emergence
of antimicrobial resistance [41]. In theory, a class of anti-
biotics or a specific antibiotic drug is withdrawn from use
for a defined time period and reintroduced at a later point
in time in an attempt to limit bacterial resistance to the
cycled antimicrobial agents [42]. However, limited clinical
data is currently available that has examined the issue of
antibiotic class changes or cycling [43].
Gerding et al evaluated cycling of aminoglycosides during
10 years at the Minneapolis Veterans Affairs Medical
Center, cycling amikacin and gentamicin [44]. Resistance
to gentamicin had emerged as a clinical problem limiting
the use of that specific aminoglycoside at this hospital.
Using cycle times of 12–51 months, these investigators
found significantly reduced resistance to gentamicin when
amikacin was used, but a return of resistance with the
rapid reintroduction of gentamicin. This was followed by
more gradual reintroduction of gentamicin a second time,
without increased levels of resistance recurring. This expe-
rience suggested that the cycling of antibiotics within the
same drug class, in some circumstances, could be an
effective strategy for curbing antimicrobial resistance.
Gruson et al observed a reduction in the incidence of ven-
tilator-associated pneumonia after introducing an anti-
microbial programme that consisted of supervised rotation
and restricted use of ceftazidime and ciprofloxacin, which
were widely prescribed before institution of the antibiotic
programme [45]. The antibiotic selection was based on
monthly reviews of the pathogens isolated from the inten-
sive care unit and their antibiotic susceptibility patterns.
These clinicians were therefore rotating antimicrobial
agents based on ‘real-time’ information that allowed
potentially more effective antibiotics to be prescribed to
their patients. They observed a decrease in the incidence
of ventilator-associated pneumonia that was primarily due
to a reduction in the number of episodes attributed to
potentially antibiotic-resistant Gram-negative bacteria,
including  P. aeruginosa,  Burkholderia cepacia, Stenotro-
phomonas maltophilia, and Acinetobacter baumanii.
Area-specific antimicrobial therapy
Variability in the pathogens associated with nosocomial
infections among hospitals, along with their antibiotic sus-
ceptibility profiles, has been demonstrated to occur [46].
Additionally, changing temporal patterns of nosocomial
pathogens and antimicrobial susceptibility over time have
been described [30,47]. This suggests that hospitals may
need to develop systems for reporting antimicrobial suscep-
tibility patterns of bacterial pathogens for individual hospital
areas or units on a regular basis because of the potential
existence of intrahospital variations. Using such data can
improve the efficacy of antimicrobial therapy by increasing
the likelihood for adequate initial treatment of infections [6].
Antimicrobial de-escalation
There is increasing clinical evidence suggesting that
failure to initially treat high-risk microbiologically docu-
mented infections (e.g. hospital-acquired pneumonia, bac-
teraemia) with an adequate initial antibiotic regimen is
associated with greater patient morbidity and mortality
[12–14]. Inadequate initial antibiotic treatment is usually
defined as either the absence of antimicrobial agents
directed against a specific class of microorganisms (e.g.
absence of therapy for fungaemia due to Candida albi-
cans) or the administration of antimicrobial agents to
which the microorganism responsible for the infection was
resistant (e.g. empiric oxacillin treatment of pneumonia
subsequently attributed to methicillin-resistant S. aureus
based on appropriate culture results).
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istration of inadequate antimicrobial treatment in patients
with hospital-acquired pneumonia include potentially
antibiotic-resistant Gram-negative bacteria (P. aeruginosa,
Acinetobacter species,  Klebsiella pneumoniae, and
Enterobacter  species) and S. aureus, especially strains
with methicillin resistance [12–14]. For patients with hos-
pital-acquired bloodstream infections, antibiotic-resistant
Gram-positive bacteria (methicillin-resistant S. aureus,
vancomycin-resistant enterococci and coagulase-negative
staphylococci),  Candida species and, less commonly,
antibiotic-resistant Gram-negative bacteria account for
most cases of inadequate antibiotic treatment [48]. Given
the increasing rates of nosocomial infections due to anti-
biotic-resistant bacteria, clinicians should consider the fol-
lowing recommendations for the initial antibiotic treatment
of hospital-acquired infections.
Risk stratification should be employed to identify those
patients at high risk for infection with antibiotic-resistant
bacteria. These risk factors include prior treatment with
antibiotics during the hospitalization, prolonged lengths of
stay in the hospital, and the presence of invasive devices
(e.g. central venous catheters, endotracheal tubes, urinary
catheters) [6,7]. Patients at high risk for infection with
antibiotic-resistant bacteria should be treated initially with a
combination of antibiotics providing coverage for the most
likely pathogens to be encountered in that specific inten-
sive care unit setting. Such an approach to initial antibiotic
treatment can be potentially modified if specific micro-
organisms are excluded based on examination of appropri-
ate clinical specimens (e.g. Gram stain of lower respiratory
tract specimens). Such empiric therapy should, however,
always be modified once the agent of infection is identified
or discontinued altogether if the diagnosis of infection
becomes unlikely. De-escalation of antibiotic therapy can
be thought of as a strategy to balance the need to provide
adequate initial antibiotic treatment of high-risk patients
with the avoidance of unnecessary antibiotic utilization,
which promotes resistance [27]. Application of this strat-
egy should become more feasible and be accepted as the
optimal duration of antibiotic therapy for specific indica-
tions and risk-stratified patient groups becomes better
identified in the hospital setting [26].
Multiple interventions (infection control and
antibiotic restriction)
Several recent experiences suggest that infection control
practices aimed at preventing horizontal transmission of
antibiotic-resistant nosocomial infections may lack
success unless they are also coupled with antimicrobial
interventions. Quale et al found, despite an intensive pro-
gramme of barrier precautions for patients with van-
comycin-resistant enterococci (VRE) (including having
VRE-positive patients in single rooms, performing
chlorhexidine perineal washes on VRE-positive patients,
using gloves and chlorhexidine soap for hand washing,
and eliminating electronic thermometers), that nearly 50%
of the inpatients at their hospital were found to have
gastrointestinal colonization with VRE [49,50]. In an
attempt to control this outbreak, the hospital formulary was
altered by restricting the use of vancomycin and third-gen-
eration cephalosporins and adding beta-lactamase
inhibitors (ampicillin/sulbactam and piperacillin/tazobactam)
because of their enhanced activity against enterococcus.
The average monthly use of ceftazidime and vancomycin
decreased by 55 and 34%, respectively, after 6 months of
implementation. This was associated with a decrease in the
point prevalence of faecal colonization with VRE from 47 to
15% (P < 0.001) as well as a decrease in the number of
patients with clinical isolates positive for VRE.
Montecalvo  et al described the impact of an enhanced
programme for the control of VRE infections in the hospi-
tal setting [51]. They developed a multifaceted interven-
tion that included cohorting of staff according to patients’
VRE status, early infectious disease consultation, isolating
patients with known VRE colonization and those whose
VRE colonization status was undetermined, and limiting
the use of specific antibiotics (e.g. vancomycin, imipenem)
in addition to their standard practices. The incidences of
VRE infection and colonization were statistically reduced,
as was use of the targeted antimicrobial agents. These
studies suggest that strategies aimed at curbing unneces-
sary antibiotic utilization along with implementation of
sound infection control practices are most likely to
succeed in terms of reducing antimicrobial resistance and
enhancing overall antimicrobial efficacy.
Conclusion
Clinicians practising in intensive care units must develop
and promote strategies for more effectively employing
antimicrobial therapy. The most successful strategies will
be multidisciplinary, involving cooperation from the phar-
macy, infection control, nursing staff, treating physicians,
and infectious disease consultants. Such programmes
should also focus both on promoting infection control
practices and employing rational antibiotic utilization
aimed at minimizing future emergence of resistance.
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